Sangamo Therapeutics Inc (NASDAQ: SGMO) is off to an incredibly strong start …
Stock
On May26, 2017, Sangamo Therapeutics, Inc. (the Company ... LLC (the Agent), to which the Company may issue and sell from time to time up to $75.0 million of common stock, par value $0.01 per share, through Cowen as the sales …
NASDAQ
As of late, it has definitely been a great time to be an investor in Sangamo Therapeutics Inc SGMO. The stock has moved higher by 90.5% in the past month, while it is also above its 20 Day SMA too. This combination of strong price …
NASDAQ
On May 26, 2017, Sangamo Therapeutics, Inc. (the "Company") entered into ... which the Company may issue and …
Financial statement
Sangamo Therapeutics (NASDAQ:SGMO) traded down 1.89% on Friday, hitting $7.80. The stock had a trading volume of 1,239,071 shares. The stock has a 50-day moving average of $5.19 and a 200-day moving average of $4.13. Sangamo
BNS8d
Earnings
NY now owns 49,713 shares of the biopharmaceutical company's stock valued at $152,000 after buying an additional 780 shares in the last quarter. Most recently Sangamo Therapeutics Inc (NASDAQ:SGMO)'s price target was revised on …
Encina Power Station
Find out which companies are about to raise their dividend well before the news hits the Street with StreetInsider.com's Dividend Insider Elite. Sign-up for a FREE trial here. ROAD TOWN, BRITISH VIRGIN ISLANDS -- (Marketwired) -- …
Special Meeting
On May 26 co entered into amended and restated at-market offering program sales agreement with Cowen and Company * Co may issue and sell from time to time up to $75.0 million of common stock, par value $0.01 per share, through …
Reuters
Vertex Pharmaceuticals, Sangamo Therapeutics and Depomed were among the biotech stock movers in premarket …
Sangamo Therapeutics